Stabilized CBD–Flavonoid Compositions for Tocopherol-Free Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gynecological disorders and cancers, particularly endometrial and ovarian cancers, are inadequate, with existing cannabinoid delivery methods potentially increasing cancerous and noncancerous lesion growth due to the use of common carriers like olive oil, which contain tocopherol, and lack effective screening options for ovarian cancer.
Innovation Solution
A composition comprising cannabidiol (CBD) and flavonoids, such as myricetin, chrysin, taxifolin, or quercetin, is used in combination with chemotherapeutic agents, avoiding tocopherol and optimizing pH for enhanced therapeutic efficacy against gynecological disorders and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If common carriers like olive oil containing tocopherol are used for CBD delivery, then CBD delivery is achieved, but cancerous and noncancerous lesion growth is increased
Solution Approach 1:
The patent extracts and removes tocopherol from the carrier oil formulation. The composition specifically excludes tocopherol while retaining other beneficial components, thereby eliminating the harmful effect of lesion growth promotion while maintaining CBD delivery effectiveness
Solution Approach 2:
The patent changes the chemical composition parameters of the carrier by specifying particular ratios of cannabinoids and excluding certain components (tocopherol). This parameter modification transforms the carrier from a lesion-promoting formulation to a lesion-inhibiting formulation while maintaining delivery function
2Device complexity
If CBD is administered alone, then simplified treatment protocol is achieved, but therapeutic efficacy is insufficient for chemoresistant cancers
Solution Approach 1:
The patent merges multiple therapeutic components into a single integrated composition: CBD, flavonoids, and chemotherapeutic agents are combined in one formulation. This merging maintains simplified administration (single dose) while achieving enhanced therapeutic efficacy through synergistic interactions between components
Solution Approach 2:
The patent creates a composite therapeutic material combining cannabinoids, flavonoids, and chemotherapeutic agents. This composite formulation leverages the complementary mechanisms of action of each component class to overcome chemoresistance while maintaining ease of administration
3Ease of manufacture
If pH is not optimized in CBD formulations, then simpler formulation process is achieved, but therapeutic efficacy is reduced
Solution Approach 1:
The patent optimizes the pH parameter of the formulation to enhance therapeutic efficacy. By adjusting and specifying the pH range, the formulation achieves improved stability and effectiveness without requiring complex manufacturing processes, maintaining ease of production
Data Source
AI summary
Compositions and methods of use of treatment of one or more of ovarian cancer, endometrial cancer, head and neck cancer, noncancerous gynecological disorders, and estrogen sensitive cancers, the composition comprising an effective amount of a cannabinoid and a flavonoid wherein the method comprises administering to a patient in need thereof an effective amount of the composition and optionally administering the composition concomitantly with a chemotherapeutic agent.